Research ArticleAccepted Article
Open Access
Canadian Rheumatologists’ Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis
Dafna D. Gladman, Michael Starr, Alfred Cividino, Anne-Julie Gaudreau, Jennifer Jelley, Denise Nicholson and Jacob Karsh
The Journal of Rheumatology May 2021, jrheum.201195; DOI: https://doi.org/10.3899/jrheum.201195
Dafna D. Gladman
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
Michael Starr
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
Alfred Cividino
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
Anne-Julie Gaudreau
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
Jennifer Jelley
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
Denise Nicholson
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
Jacob Karsh
From the Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; McGill University Health Center, Montreal, Québec, Canada; McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada; Amgen Inc., Mississauga, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada. This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Celgene had a role in the study design and in the collection, analysis, and interpretation of the data, and revising of the manuscript. Amgen Inc. had a role in revising the report and the decision to submit the report for publication. Conflicts of interest: D. D. Gladman has received grant/research support and served as a consultant for AbbVie, Amgen Inc., Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, and UCB. M. Starr has served as a consultant for AbbVie, Amgen Inc., Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. A. Cividino has received grant/research support from and served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, and Pfizer. AJ Gaudreau, J. Jelley, and D. Nicholson are employees of Amgen Inc. J. Karsh has received honoraria from AbbVie, Celgene, Eli Lilly, and Novartis/Sandoz, and served as an external consultant to the Canadian Agency for Drugs and Technology in Health (CADTH). Acknowledgments: Writing support was funded by Celgene and Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Address correspondence to Dr. D. D. Gladman, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. Email: dafna.gladman@utoronto.ca.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Canadian Rheumatologists’ Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis
Dafna D. Gladman, Michael Starr, Alfred Cividino, Anne-Julie Gaudreau, Jennifer Jelley, Denise Nicholson, Jacob Karsh
The Journal of Rheumatology May 2021, jrheum.201195; DOI: 10.3899/jrheum.201195
Accepted manuscript
Canadian Rheumatologists’ Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis
Dafna D. Gladman, Michael Starr, Alfred Cividino, Anne-Julie Gaudreau, Jennifer Jelley, Denise Nicholson, Jacob Karsh
The Journal of Rheumatology May 2021, jrheum.201195; DOI: 10.3899/jrheum.201195